SCHEMBL29978071

SCHEMBL29978071

COc1ccccc1N(C)S(=O)(=O)c1ccc(C(=O)Nc2nc(-c3ccccn3)cs2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.74
ADORA3 P0DMS8 7/20 0.64
KDM4A O75164 4/20 0.64
KDM4B O94953 4/20 0.64
KDM5B Q9UGL1 4/20 0.64
KDM5C P41229 2/20 0.64
GRM1 Q13255 1/20 0.59
MAPK1 P28482 2/20 0.58
KDM4E B2RXH2 2/20 0.58
MAPT P10636 2/20 0.58
HTT P42858 2/20 0.58
LMNA P02545 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
NPC1 O15118 1/20 0.56
USP2 O75604 1/20 0.56
ALOX15 P16050 1/20 0.56
MEN1 O00255 1/20 0.56
ALDH1A1 P00352 1/20 0.56
KMT2A Q03164 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL665201 1.00 SMN1; SMN2 (0.74) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL29978560 0.86 ADORA3 (0.75) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL664225 0.86 ADORA3 (0.75) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL664484 0.85 ADORA3 (0.66) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL29978117 0.85 ADORA3 (0.66) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL663246 0.85 MEN1 (0.71) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL21376512 0.84 ADORA3 (0.66) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL662995 0.84 GRM1 (0.73) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL29978012 0.84 GRM1 (0.73) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B
SCHEMBL21376336 0.83 SMN1; SMN2 (0.51) SMN1; SMN2ADORA3KDM4AKDM4BKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-20230110928-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL STEMSYNERGY THERAPEUTICS, INC. 2023-04-13 US disclosed
US-11512081-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell STEMSYNERGY THERAPEUTICS, INC. (US) 2022-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834446-B2 Methods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell WNT3A, WNT1, WNT3 SMN1; SMN2 3313/4885ADORA3 3744/4885KDM4A 3541/4885
US-20230110928-A1 METHODS AND COMPOSITIONS USEFUL IN TREATING CANCER AND REDUCING WNT MEDIATED EFFECTS IN A CELL WNT3A, WNT1, WNT3 SMN1; SMN2 3313/4885ADORA3 3744/4885KDM4A 3541/4885
US-11512081-B2 Methods and compositions useful in treating cancer and reducing WNT mediated effects in a cell WNT3A, WNT1, WNT3 SMN1; SMN2 3313/4885ADORA3 3744/4885KDM4A 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.